<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03678428</url>
  </required_header>
  <id_info>
    <org_study_id>TRIUMPH</org_study_id>
    <nct_id>NCT03678428</nct_id>
  </id_info>
  <brief_title>FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM</brief_title>
  <official_title>FUDR/Oxaliplatin HAI Plus Irinotecan Chemotherapy vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus&#xD;
      CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic&#xD;
      colorectal cancer liver metastases. The patients will be treated with systemic FOLFOXIRI&#xD;
      chemotherapy or FUDR/Oxaliplatin hepatic arterial infusion with CPT-11 systemic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies and our experience have proved the efficacy and safety of systemic&#xD;
      chemotherapy combined with hepatic arterial infusion (HAI) with floxuridine and dexamethasone&#xD;
      in patients with initially unresectable colorectal liver metastasis. Hepatic arterial&#xD;
      infusion oxaliplatin trials have been done with oxaliplatin alone and in combination with&#xD;
      irinotecan, 5-FU/LV, and mitomycin-C and have showed that Hepatic arterial infusion&#xD;
      oxaliplatin and FUDR could increase response rate and resection rate for colorectal liver&#xD;
      metastasis. Therefore, we designed this study to compare objective response rates of&#xD;
      FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially&#xD;
      non-resectable metastatic colorectal cancer liver metastases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate and bilateral 95% confidence interval</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as complete remission rates and partial remission rates after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rates</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as no macroscopic or microscopic residual tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of tumor regression(DpR)</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the largest depth of tumor regression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free Survival(PFS)</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the period from the date of receiving treatment to disease progress caused by any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival(RFS) of patients with resectable tumor</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the period from the date of resection to tumor relapse caused by any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the period from the date of receiving treatment to death caused by any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, servere adverse events and surgery-related adverse events rates</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the incidence and severity of adverse events related to chemotherapy, HAI and surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>FUDR/Oxaliplatin HAI plus irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:&#xD;
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.&#xD;
then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.&#xD;
This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Systemic FOLFOXIRI every 28 days:&#xD;
Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>FUDR/Oxaliplatin HAI plus irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin HAI</intervention_name>
    <description>Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.</description>
    <arm_group_label>FUDR/Oxaliplatin HAI plus irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <description>0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.</description>
    <arm_group_label>FUDR/Oxaliplatin HAI plus irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin 200mg/m2 IV on Day 1 and 15.</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤70.&#xD;
&#xD;
          -  Diagnosed as colorectal adenocarcinoma by histology.&#xD;
&#xD;
          -  Confirmed as liver metastases by medical imaging or pathology.&#xD;
&#xD;
          -  MDT determined as unresectable liver metastases, defined as:①more than 5 metastases;&#xD;
             ②unable to conduct R0 resection; ③no sufficient residual liver volume after resection;&#xD;
             ④none of 3 hepatic vein can be reserved after resection, no sufficient blood supply or&#xD;
             bibliary duct can be reserved, none of 2 adjacent liver segment can be reserved.&#xD;
             Whenever meets any of the criteria mentioned above would be defined as unresectable&#xD;
             liver metastases.&#xD;
&#xD;
          -  No previous treatment aiming at treating liver metastases, including chemotherapy,&#xD;
             surgery, radiotherapy, transcatheter hepatic arterial chemoembolization(TACE) or&#xD;
             target therapy.&#xD;
&#xD;
          -  Confirmed by CT, MRI or PET/CT(if necessary) that there is no extrahepatic metastases&#xD;
             or only oligos extrahepatic metastases(no more than 2 organs and 5 leisions, maximum&#xD;
             diameters of single leision ≤ 1cm).&#xD;
&#xD;
          -  Unsuitable for cetuximab treatment(RAS mutation, unable to afford the cost).&#xD;
&#xD;
          -  No hematologic dysfunction(Platelets &gt;90×10^9/L; WBC &gt;3×10^9/L; Neutrophil&#xD;
             &gt;1.5×109/L).&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 × ULN; aminotransferase ≤ 5 × ULN.&#xD;
&#xD;
          -  No ascites; no coagulation dysfunction; albumin ≥ 30g/L.&#xD;
&#xD;
          -  Hepatic function was classified as class A by Child-Pugh classification.&#xD;
&#xD;
          -  Serum creatinine &lt; 1 × ULN, or creatinine clearance rate(CCR) &gt; 50ml/min(calculated by&#xD;
             Cockcroft-Gault formula).&#xD;
&#xD;
          -  ECOG scored as 0-1.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
          -  Willing and able to receive follow-up until death or trial is finished or trial is&#xD;
             terminated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of extensive extrahepatic metastases(more than 2 organs and 5 leisions, or&#xD;
             maximum diameter of single leision &gt; 10 cm).&#xD;
&#xD;
          -  Severe arterial embolism or ascites.&#xD;
&#xD;
          -  Presence of hemorrhagic tendency or coagulation dysfunction.&#xD;
&#xD;
          -  Presentive of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
          -  Severe uncontrolled systemic complications, such as infection or diabetes.&#xD;
&#xD;
          -  Severe clinical CVD(cardiovascular disease), such as cerebrovascular accident(within 6&#xD;
             months before recruitment), myocardial infarction(within 6 months before recruitment),&#xD;
             uncontrolled hypertension; unstable angina pectoris; congestive heart-failure(NYHA 2-4&#xD;
             grade); arrhythmia that needs medication treatment.&#xD;
&#xD;
          -  Previous diagnosed or physical examination showed presence of central nervous&#xD;
             system(CNS) disease(i.e. primary brain tumor, epilepsy uncontrolled by standard&#xD;
             treatment, any history of brain metastases or stroke).&#xD;
&#xD;
          -  Previous history of other malignancy within 5 years(except basal cell carcinoma after&#xD;
             radical resection and/or cervical carcinoma in situ).&#xD;
&#xD;
          -  Received any medication under research within 28 days before the trial.&#xD;
&#xD;
          -  Any residual toxicity of previous chemotherapy(except hair loss), i.e. peripheral&#xD;
             neuropathy ≥ NCI CTC v3.0 Grade 2, will be excluded from oxaliplatin-based&#xD;
             chemotherapy regimen research pair.&#xD;
&#xD;
          -  Allergic to any medication involved in the trial.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Patient who does not use or refuses to take any appropriate contraceptive measures&#xD;
             (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel&#xD;
             or sterilization operation), including women of childbearing age (within 2 years after&#xD;
             the last menstrual period) and men who are with possible fertility.&#xD;
&#xD;
          -  Unable or unwilling to comply with the research plan.&#xD;
&#xD;
          -  The existence of any other disease, dysfunction caused by metastatic lesions, or&#xD;
             suspicious disease found on the regular examination, which indicating&#xD;
             contraindications to the use of study drugs or may bring high risks of treatment&#xD;
             related complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuhong Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuhong Li, MD</last_name>
    <phone>+86(20)87343135</phone>
    <email>liyh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>October 27, 2019</last_update_submitted>
  <last_update_submitted_qc>October 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Director, Department of Medical Oncology, Principal Investigator, Clinical Professor, Yuhong Li</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

